This inventor holds 4 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 3 EPO patents. Top assignees: Biontech Se, Biontech Ag, Biontech Rna Pharmaceuticals Gmbh. Active years: 2019-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 76 
1 out of 37 
1 out of 19 Years Active: 2019-2025
Title: Christoph Hartmann: Innovator in Cancer Research
Introduction
Christoph Hartmann is a significant figure in the field of cancer research, based in Frankfurt-am-Main, Germany. He has been instrumental in advancing medical technology, contributing to the understanding and treatment of various types of cancer through his innovative work. With three patents to his name, Hartmann's inventions focus on tumor antigens and methods for cancer diagnosis and treatment.
Latest Patents
His most recent patents include groundbreaking developments in tumor antigens for determining cancer therapy, particularly targeting breast cancer, including triple-negative breast cancer. This invention outlines methods and compositions that utilize specific tumor antigens to enhance cancer treatment. Additionally, his patent concerning methods and compositions for the diagnosis and treatment of cancer identifies nucleic acid and amino acid sequences characteristic of tumor tissues, which serve as potential targets for therapy or diagnosis of central nervous system tumors, such as gliomas and glioblastomas.
Career Highlights
Throughout his career, Christoph Hartmann has collaborated with leading companies in the pharmaceutical and biomedical sectors. Notably, he has worked with BioNTech AG, a pioneering company known for its contributions to cancer immunotherapy. He has also been associated with Translational Oncology at the University Medical Center Mainz, further solidifying his role in advancing research in oncology.
Collaborations
Hartmann's collaborative spirit has led him to work alongside distinguished colleagues, including Ugur Sahin and Claudia Paret. These collaborations have been critical in driving innovative solutions and translating scientific discoveries into applicable therapies for cancer patients.
Conclusion
In summary, Christoph Hartmann's contributions to cancer research through his patented innovations underscore his commitment to enhancing treatment methods and diagnostic capabilities for various cancers. His work demonstrates the vital intersection of research and practical application in the ongoing fight against cancer, positioning him as an influential innovator in the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile